TSHA - tayshagtx.com Return on Sales by Net Profit

Taysha Gene Therapies Inc - graphic logo of issuer TSHA

The net profit margin helps assess the macro-stability of Taysha Gene Therapies (TSHA), whose research remains independent of market cycles. The current value of this metric is -2844.60, which correlates with the capital expenditure for the development of Rett syndrome therapy. Creating unique medications for children with brain pathologies grants the company monopolist status and guarantees long-term patent revenues.

Taysha Corp (TSHA) - Net Profit Rate from 07/04/2022 to 11/20/2026

Taysha (TSHA) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
- market capitalization statistics:
Initial company analysis:Taysha Gene Therapies
Manufactured product of Taysha Gene Therapies Inc

Developing gene therapies for CNS diseases requires colossal investments, making the monitoring of revenue efficiency critical for Taysha Gene Therapies (TSHA). By assessing the ratio of net profit to sales volume on a daily basis, this level of commercial profitability allows investors to track the actual cost of drug development and the degree of the business's financial stability between reporting cycles.

Competing companies

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|QURE (uniQure) - Net Return on Sales|MeiraGTx Corp (MGTX) - Net Margin|Regenxbio - Net Profit Rate|Net Margin solidbio.com|Net Margin ocugen.com OCGN|Net Sales Margin PACB|Benitec - Net Return on Sales|Net Margin Design Therapeutics DSGN|Net Sales Margin Rocket Pharmaceuticals RCKT|Net Profit Margin 4D Molecular Corp|LXEO: Net Margin|KRRO (Korro Bio, Inc) - Return on Sales by Net Profit|Editas Medicine (EDIT) - Net Sales Margin|Net Margin Silence Therapeutics Inc.|Net Return on Sales PRQR (proqr.com)|Net Margin Codexis Bio (CDXS)|Net Sales Margin sangamo.com (SGMO)|Net Margin nautilus.bio NAUT|Company Sales Margin Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Net Sales Margin|GBIO - Net Sales Margin|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX